Zhejiang Xinguang Pharmaceutical Co Ltd (300519) — Net Asset Quality Index
Zhejiang Xinguang Pharmaceutical Co Ltd (300519) has a Net Asset Quality Index of 92.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥893.41 Million minus total liabilities of CN¥65.46 Million yields net assets of CN¥827.95 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 300519 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Xinguang Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2011–2024)
This chart shows how Zhejiang Xinguang Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 92.7%, representing net assets of CN¥827.95 Million against total assets of CN¥893.41 Million CNY. See Zhejiang Xinguang Pharmaceutical Co Ltd (300519) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Zhejiang Xinguang Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Xinguang Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Zhejiang Xinguang Pharmaceutical Co Ltd market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 91.3% | CN¥830.53 Million | CN¥909.78 Million | CN¥79.25 Million | ▲ +0.6 pp |
| 2023 | 90.7% | CN¥844.12 Million | CN¥930.41 Million | CN¥86.29 Million | ▲ +1.0 pp |
| 2022 | 89.7% | CN¥858.89 Million | CN¥957.76 Million | CN¥98.86 Million | ▼ -1.1 pp |
| 2021 | 90.8% | CN¥846.22 Million | CN¥932.40 Million | CN¥86.19 Million | ▼ -2.1 pp |
| 2020 | 92.8% | CN¥826.94 Million | CN¥890.79 Million | CN¥63.84 Million | ▼ 0.0 pp |
| 2019 | 92.9% | CN¥799.71 Million | CN¥861.13 Million | CN¥61.42 Million | ▲ +1.3 pp |
| 2018 | 91.6% | CN¥753.26 Million | CN¥822.50 Million | CN¥69.24 Million | ▲ +0.5 pp |
| 2017 | 91.1% | CN¥705.81 Million | CN¥775.05 Million | CN¥69.24 Million | ▼ -0.3 pp |
| 2016 | 91.4% | CN¥640.46 Million | CN¥700.95 Million | CN¥60.49 Million | ▲ +6.1 pp |
| 2015 | 85.3% | CN¥309.35 Million | CN¥362.87 Million | CN¥53.52 Million | ▲ +3.1 pp |
| 2014 | 82.2% | CN¥249.00 Million | CN¥303.10 Million | CN¥54.10 Million | ▲ +0.1 pp |
| 2013 | 82.0% | CN¥201.97 Million | CN¥246.26 Million | CN¥44.29 Million | ▲ +16.9 pp |
| 2012 | 65.1% | CN¥141.62 Million | CN¥217.44 Million | CN¥75.82 Million | ▲ +17.6 pp |
| 2011 | 47.6% | CN¥104.32 Million | CN¥219.35 Million | CN¥115.03 Million | — |